title: The effect of 6% Hydroxyethyl starch vs. Ringer's lactate on acute kidney injury after renal ischemia in rats.
abstract: OBJECTIVE
  To compare fluid replacement therapy with Hydroxyethyl starch 6% (HES) versus Ringer's lactate (RL) in a rodent model of non-septic renal ischemia.
  
  
  METHODS
  Forty male Wistar rats were randomized to receive HES 2 ml.kg(-1).hr(-1) or RL 5 ml.kg(-1).hr(-1) that underwent 30 minutes of renal ischemia followed by reperfusion. Twelve hours after kidney ischemia, the kidneys were evaluated for histological changes. Serum NGAL levels were obtained at different times of the experimental protocol.
  
  
  RESULTS
  Rodents in the HES group had a median (IQR) grade of renal injury 3 (3 to 5) compared to 2 (2 to 4) in the RL group (p=0.03). NGAL levels were not associated with the severity of kidney injury.
  
  
  CONCLUSIONS
  Hydroxyethyl starch administration caused more kidney injury than Ringer's lactate in a non-infectious model of renal hypoperfusion.
authors: Postgraduate Program in Anesthesiology, Botucatu Medical School, UNESP, Sao Paulo, Brazil.
authors: Vera Lucia Fernandes de
authors: VL
authors: Azevedo
authors: Paulo Sergio Santana
authors: PS
authors: Santos
authors: Gildàsio Silveira de
authors: GS
authors: Oliveira
authors: Gabriel Pinheiro
authors: GP
authors: Módolo
authors: Maria Aparecida Custódio
authors: MA
authors: Domingues
authors: Yara Marcondes Machado
authors: YM
authors: Castiglia
authors: Pedro Thadeu Galvão
authors: PT
authors: Vianna
authors: Luiz Antonio
authors: LA
authors: Vane
authors: Norma Sueli Pinheiro
authors: NS
authors: Módolo
mesh_terms: D058186:Acute Kidney Injury / Q000473:pathology / Q000628:therapy*; D000209:Acute-Phase Proteins; D000818:Animals; D005440:Fluid Therapy / Q000379:methods; D006439:Hemodynamics; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D007511:Ischemia / Q000473:pathology / Q000628:therapy*; D007552:Isotonic Solutions / Q000627:therapeutic use*; D007668:Kidney / Q000098:blood supply* / Q000473:pathology; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood; D008297:Male; D015513:Oncogene Proteins / Q000097:blood; D010952:Plasma Substitutes / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D000077325:Ringer's Lactate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000209:Acute-Phase Proteins; D006895:Hydroxyethyl Starch Derivatives; D007552:Isotonic Solutions; D000071068:Lipocalin-2; D054834:Lipocalins; D015513:Oncogene Proteins; D010952:Plasma Substitutes; D000077325:Ringer's Lactate; C071332:Lcn2 protein, mouse